Trial Profile
Factors Influencing Response to One BoNT-A Injection Cycle in Subjects Suffering From Idiopathic Cervical Dystonia
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Torticollis
- Focus Therapeutic Use
- Acronyms INTEREST IN CD1
- Sponsors Ipsen
- 28 Nov 2018 New trial record
- 09 Oct 2018 Results from INTEREST IN CD1 [NCT00833196] INTER- EST IN CD2 [NCT01753349] and ANCHOR-CD [NCT01314365] describing the use of injection guidance (at baseline/ first injection visit and at 1 year) in 585 subjects, presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders.
- 09 Oct 2018 Results from INTEREST IN CD1 [NCT00833196] INTER- EST IN CD2 [NCT01753349] and ANCHOR-CD [NCT01314365] describing the patterns of Cervical dystonia and injection parameters in subjects routinely treated with aboBoNT-A over 1 year (N=585), presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders.